新药审批信达生物 IBI30328月5日,信达生物宣布其研发的创新口服小分子GLP-1R激动剂IBI3032获FDA新药临床试验申请(IND)批准。恒瑞医药 瑞康曲妥珠单抗8月6日,恒瑞医药宣布,其ADC创新药注射用瑞康曲妥珠单抗(商品名:艾维达®)联合阿得贝利单抗(商品名:艾瑞利®)和化疗用于胃癌或胃食管结合部腺癌适应症获得FDA孤儿药资格认定(ODD)。正大天晴 罗伐昔替尼片8月7日,正大天晴...
Source Link新药审批信达生物 IBI30328月5日,信达生物宣布其研发的创新口服小分子GLP-1R激动剂IBI3032获FDA新药临床试验申请(IND)批准。恒瑞医药 瑞康曲妥珠单抗8月6日,恒瑞医药宣布,其ADC创新药注射用瑞康曲妥珠单抗(商品名:艾维达®)联合阿得贝利单抗(商品名:艾瑞利®)和化疗用于胃癌或胃食管结合部腺癌适应症获得FDA孤儿药资格认定(ODD)。正大天晴 罗伐昔替尼片8月7日,正大天晴...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.